Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: A phase I study of the Gynecologic Oncology Group

Oncology Group ◽

Peritoneal Carcinoma

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.11.024 ◽

2016 ◽

Vol 140 (2) ◽

pp. 204-209 ◽

Cited By ~ 22

Author(s):

Lisa M. Landrum ◽

William E. Brady ◽

Deborah K. Armstrong ◽

Kathleen N. Moore ◽

Paul A. DiSilvestro ◽

...

Keyword(s):

Phase I ◽

Phase I Trial ◽

Liposomal Doxorubicin ◽

Gynecologic Oncology ◽

Oncology Group ◽

Fallopian Tube Cancer ◽

Oncology Group Study ◽

Platinum Sensitive

A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2010.12.358 ◽

2011 ◽

Vol 121 (2) ◽

pp. 264-268 ◽

Cited By ~ 16

Author(s):

Mark A. Morgan ◽

Michael W. Sill ◽

Keiichi Fujiwara ◽

Benjamin Greer ◽

Stephen C. Rubin ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase I Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Primary Peritoneal Carcinoma

A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.08.001 ◽

2017 ◽

Vol 147 (2) ◽

pp. 283-290 ◽

Cited By ~ 13

Author(s):

Premal H. Thaker ◽

William E. Brady ◽

Heather A. Lankes ◽

Kunle Odunsi ◽

William H. Bradley ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase I Trial ◽

Liposomal Doxorubicin ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.053 ◽

2015 ◽

Vol 137 ◽

pp. 23

Author(s):

L.M. Landrum ◽

W.E. Brady ◽

D.K. Armstrong ◽

K.N. Moore ◽

P.A. DiSilvestro ◽

...

Keyword(s):

Phase I ◽

Phase I Trial ◽

Liposomal Doxorubicin ◽

Gynecologic Oncology ◽

Oncology Group ◽

Fallopian Tube Cancer ◽

Oncology Group Study ◽

Platinum Sensitive

A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.08.037 ◽

2012 ◽

Vol 127 (3) ◽

pp. 506-510 ◽

Cited By ~ 8

Author(s):

Natalie Gould ◽

Michael W. Sill ◽

Robert S. Mannel ◽

Premal H. Thaker ◽

Paul A. DiSilvestro ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase I Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Primary Peritoneal Carcinoma

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.417 ◽

2012 ◽

Vol 125 (1) ◽

pp. 54-58 ◽

Cited By ~ 5

Author(s):

Natalie Gould ◽

Michael W. Sill ◽

Robert S. Mannel ◽

P.H. Thaker ◽

Paul DiSilvestro ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase I Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Primary Peritoneal Carcinoma

Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group

Journal of Gynecologic Oncology ◽

10.3802/jgo.2020.31.e5 ◽

2020 ◽

Vol 31 (1) ◽

Cited By ~ 1

Author(s):

Chyong-Huey Lai ◽

Elizabeth Vallikad ◽

Hao Lin ◽

Lan-Yan Yang ◽

Shih-Ming Jung ◽

...

Keyword(s):

Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Gynecologic Oncology ◽

Randomized Study ◽

Advanced Ovarian Cancer ◽

Oncology Group

A Phase I Trial of Prolonged Oral Etoposide and Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2002.6584 ◽

2002 ◽

Vol 85 (1) ◽

pp. 136-139 ◽

Cited By ~ 7

Author(s):

Peter G. Rose ◽

Michael Rodriguez ◽

Joan Walker ◽

Benjamin Greer ◽

Nancy Fusco ◽

...

Keyword(s):

Phase I ◽

Phase I Trial ◽

Liposomal Doxorubicin ◽

Gynecologic Oncology ◽

Oral Etoposide ◽

Oncology Group ◽

Oncology Group Study

Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group

Gynecologic Oncology ◽

10.1016/j.ygyno.2010.10.018 ◽

2011 ◽

Vol 120 (2) ◽

pp. 224-228 ◽

Cited By ~ 28

Author(s):

Charles A. Kunos ◽

Michael W. Sill ◽

Thomas E. Buekers ◽

Joan L. Walker ◽

Jeanne M. Schilder ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Epithelial Ovarian Cancer ◽

Phase I Study ◽

Low Dose ◽

Gynecologic Oncology ◽

Oncology Group

A phase II, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A Gynecologic Oncology Group partners study

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.03.507 ◽

2017 ◽

Vol 145 ◽

pp. 220-221

Author(s):

B.J. Monk ◽

M.F. Brady ◽

C. Aghajanian ◽

H. Lankes ◽

T. Rizack ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Gynecologic Oncology ◽

Controlled Study ◽

Oncology Group ◽

Double Blind ◽

Double Blind Placebo